Stockreport

AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Program and Reports Compelling Preclinical Data Supporting the Potential of its Dual-Vector Technology

Applied Genetic Technologies Corporation  (AGTC) 
Last applied genetic technologies corporation earnings: 2/5 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.agtc.com/investor-relations
PDF - Simultaneous delivery of two optimized AAV vectors expands the therapeutic and commercial potential of AGTC's industry-leading AAV platform by enabling delivery of DNA [Read more]